Renishaw Plc · LSE:RSW
Renishaw — Investor Day (May 2016)
39 slides from Renishaw's investor day presentation, May 12, 2016
Slide 1: Neurological Products
Neurological Products Paul Skinner Operations Manager Neurological Products Division Renishaw plc
Slide 2: Note on slides differing from Investor Day
NB please note that some of the following slides vary slightly from those used at the Investor Day on the 12th May due to the reformatting of some of the animated slides.
Slide 3: Neurological Products
Neurological Products Renishaw is applying precision engineering technology to the challenges of functional neurosurgery. Our aim is to help leading clinicians to enhance the safety and cost-effectiveness of their procedures, improving patient outcomes through accurate delivery of implantable device
Slide 4: Our target market
Our target market Our target market is Neurosurgical Centres. Specifically centres specialising in stereotactic neurosurgery (the delivery of instruments and/or devices accurately and repeatability into the brain) These units require; • High accuracy – specific placement of devices and instruments i
Slide 5: Examples of Neurosurgical procedures
Examples of Neurosurgical procedures • DBS - Deep Brain Stimulation – Accurate placement of electrodes into small structures of the brain – Typically for treating the symptoms of movement disorders such as Parkinson's disease • SEEG – Stereoelectroencephalography – Diagnostic procedure for Epilepsy
Slide 6: Engineering solutions – a systems approach
Engineering solutions – a systems approach
Slide 7: neuromate stereotactic robot
neuro I mate® stereotactic robot • The first image-guided neurosurgical robot in the world • Used in over 10,000 neurosurgical procedures • More than 30 scientific peer-reviewed publications • CE marked & cleared for sale in the USA • In use in leading neurosurgical centres in France, UK, Italy, Ger
Slide 8: Improved precision and increased speed
Improved precision and increased speed* Precision Average Range DBS2 Frame 1.03 mm 0.62 mm - 1.44 mm Robot 0.81 mm 0.33 mm - 1.29 mm SEEG1 Frame 1.43 mm 0.91 mm - 2.21 mm Robot 0.78 mm 0.49 mm - 1.08 mm Speed Average Range DBS2 Frame 55 min +/- 17 min Robot 23 min +/-13 min *Compared to other stereo
Slide 9: neuroinspire surgical planning platform
neuro I inspire™ surgical planning platform • Rapid, accurate planning of stereotactic surgeries • Multi-planar image reconstruction • Brain atlas to provide reference features during planning • Intuitive planning process • Detailed modelling of implanted devices • Manual anatomy segmentation
Slide 10: neurolocate advanced patient registration system
neuro | locate™ - advanced patient registration system neurolocate™ is a new frameless patient registration module for use with the Renishaw neuromate® stereotactic robot. • Potential for time and cost saving by utilising the benefits of intraoperative imaging in the operating room; • Improved patie
Slide 11: neuroguide DBS electrode delivery system
neuro | guide™ DBS electrode delivery system • Allows verification of expected DBS lead position relative to targeted anatomy using MRI data • Guide tube: permanent implant secured to the skull that acts as electrode conduit • Stylette: temporary implant for peri-operative MRI/CT confirmation
Slide 12: Consumables and tooling – DIXI medical
Consumables and tooling – DIXI medical • Renishaw is an exclusive distributor for DIXI medical in UK & Ireland; • DIXI are a manufacturer of specialist electrodes and instruments for use in stereotactic neurosurgery; • Such as; • depth electrodes • biopsy needles • cortical grids • accessories
Slide 13: Drug delivery – support for Clinician led study
Drug delivery – support for Clinician led study • Manufacturing an investigational intraparenchymal drug delivery system for an NHS Trust provider • Clinician-led Phase II trial under way to deliver a drug for the treatment of Parkinson’s disease • This system has also been used by the Trust for del
Slide 14: Successful outcomes - Epilepsy
Successful outcomes - Epilepsy • Stella (aged 13) developed severe epilepsy when she was 1 year old and subsequently endured up to 100 life threatening seizures every day. • Over 10 years, she underwent 5 invasive surgical procedures, and after every procedure, the seizures returned immediately, oft
Slide 15: Successful outcomes - Epilepsy
Successful outcomes - Epilepsy • Their last hope was at the Niguarda Ca’ Granda hospital in Milan, Italy where the neurosurgical team are pioneering the use of the Renishaw neuromate® stereotactic robot for the treatment of epilepsy (SEEG). • Due to the precision and stability of the neuromate robot
Slide 16: Targeted drug delivery to the brain: What is the potential?
Clinical – The Bristol/Renishaw collaboration Targeted drug delivery to the brain What is the potential? Mr Neil Barua PhD, FRCS(SN) Department of Neurosurgery Southmead Hospital Bristol
Slide 17: Drug delivery to the brain – what is the challenge?
Drug delivery to the brain – what is the challenge? • The blood brain barrier (BBB) – nature’s defence mechanism – Prevents transfer of drugs from the bloodstream into the brain – The BBB is considered to be the single most important limiting factor in developing effective therapies for neurological
Slide 18: Drug delivery to the brain – what is the solution?
Drug delivery to the brain – what is the solution? • Convection-enhanced drug delivery – Direct delivery of drugs into the brain – Highly accurate placement of microcatheters into the brain – Controlled infusion of drugs – Distribution of infusate through large brain volumes
Slide 19: The solution – an implantable catheter system
The solution – an implantable catheter system
Slide 20: Direct drug delivery to the brain: The Bristol/Renishaw Experience
Direct drug delivery to the brain The Bristol/Renishaw Experience
Slide 21: The surgical process – pre-operative MRI scanning
The surgical process – pre-operative MRI scanning
Slide 22: neuroinspire – surgical planning software
neuroinspire – surgical planning software Source: Renishaw neuroinspire software
Slide 23: Automatic identification of brain structures
Automatic identification of brain structures Source: Renishaw neuroinspire software
Slide 24: Trajectory Planning
Trajectory Planning Source: Renishaw neuroinspire software
Slide 25: Safe surgical trajectories
Safe surgical trajectories Source: Renishaw neuroinspire software
Slide 26: neuromate – Robot assisted surgery
neuromate – Robot assisted surgery
Slide 27: Source: Renishaw neuroinspire software
Source: Renishaw neuroinspire software
Slide 28: Accuracy of catheter placement ± 0.7 mm
Accuracy of catheter placement ± 0.7 mm Source: Renishaw neuroinspire software
Slide 29: Infusion of a test agent
Infusion of a test agent Source: Renishaw neuroinspire software
Slide 30: Repeated drug administration
Repeated drug administration
Slide 31: Transcutaneous bone-anchored port
Transcutaneous bone-anchored port
Slide 32: Attachment of administration set
Attachment of administration set
Slide 33: Treatment of brain tumours with chemotherapy infusions
Treatment of brain tumours with chemotherapy infusions • 4 adults with progressive/recurrent glioblastoma – average survival less than 1 year • 11 children with brainstem glioma – average survival 7 to 9 months
Slide 34: 1st patient 52 years old Recurrent glioblastoma
• 1st patient - 52 years old - Recurrent glioblastoma - 2 previous surgeries - Radiotherapy & chemotherapy Source: Renishaw neuroinspire software
Slide 35: Renishaw apply innovation
RENISHAW< apply innovation™
Slide 36: 12 year old boy with brainstem tumour
12 year old boy with brainstem tumour Dec 2014 Jan 2015 March 2015
Slide 37: Direct drug delivery to the brain – what is the potential?
Direct drug delivery to the brain – what is the potential? • Largest experience worldwide of repeated drug infusions • Application to a wide range of neurological diseases – Parkinson’s Disease, brain tumours, Alzheimer’s Disease… • Unique and world-leading technology • Technology allows delivery of
Slide 38: Renishaw Healthcare Centre of Excellence
Renishaw Healthcare Centre of Excellence • Training is an important part of product development and beyond • Familiar operating environment will ensure realistic conditions/feedback • Brings manufacturing process expertise to the Operating theatre • State-of-the-art training facility includes; – Ful
Slide 39: Thank you
RENISHAW< apply innovation™ Thank you